CAPS Plus: A Clinical Biomarker Scoring System to Predict Aβ Positivity and Facilitate Enrollment in Anti-Amyloid Clinical Trials
CAPS Plus is potentially a useful screening tool for enrollment in anti-Aβ therapy and clinical trials for AD, specifically addressing people with prodromal and mild AD.
Authors
- Carlos Roncero (ORCID: https://orcid.org/0000-0002-8712-0843)
- Cheryl L. Wellington (ORCID: https://orcid.org/0000-0001-7014-039X)
- Durjoy Lahiri
- Jennifer G. Cooper
- Bruna Seixas-Lima
- Howard Chertkow
Publication Details
- Journal
- Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques
- Published
- 2026-01-20
- DOI
- https://doi.org/10.1017/cjn.2026.10530
- Primary Topic
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00